479 reports of this reaction
4.3% of all FARICIMAB reports
#3 most reported adverse reaction
VISUAL IMPAIRMENT is the #3 most commonly reported adverse reaction for FARICIMAB, manufactured by Genentech, Inc.. There are 479 FDA adverse event reports linking FARICIMAB to VISUAL IMPAIRMENT. This represents approximately 4.3% of all 11,141 adverse event reports for this drug.
Patients taking FARICIMAB who experience visual impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISUAL IMPAIRMENT is moderately reported among FARICIMAB users, representing a notable but not dominant share of adverse events.
In addition to visual impairment, the following adverse reactions have been reported for FARICIMAB:
The following drugs have also been linked to visual impairment in FDA adverse event reports:
VISUAL IMPAIRMENT has been reported as an adverse event in 479 FDA reports for FARICIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISUAL IMPAIRMENT accounts for approximately 4.3% of all adverse event reports for FARICIMAB, making it one of the most commonly reported side effect.
If you experience visual impairment while taking FARICIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.